Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11205659rdf:typepubmed:Citationlld:pubmed
pubmed-article:11205659lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:11205659lifeskim:mentionsumls-concept:C0027707lld:lifeskim
pubmed-article:11205659lifeskim:mentionsumls-concept:C0021390lld:lifeskim
pubmed-article:11205659lifeskim:mentionsumls-concept:C0127615lld:lifeskim
pubmed-article:11205659lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:11205659pubmed:issue2lld:pubmed
pubmed-article:11205659pubmed:dateCreated2001-2-5lld:pubmed
pubmed-article:11205659pubmed:abstractTextMesalamines are slow-release formulations of 5-aminosalicylic acid (5-ASA) and are effective as primary treatment and maintenance therapy in inflammatory bowel disease. Interstitial nephritis is a recognized side effect. We report two cases of biopsy-confirmed interstitial nephritis in patients being treated with 5-ASA. Both had a trial of steroid therapy. One patient had partial recovery of renal function but the other patient was in chronic renal failure and likely was approaching the need for dialysis. Interstitial nephritis is an under-recognized complication of 5-ASA therapy. Early identification and withdrawal of this drug can lead to a partial or complete reversal of renal dysfunction.lld:pubmed
pubmed-article:11205659pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11205659pubmed:languageenglld:pubmed
pubmed-article:11205659pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11205659pubmed:citationSubsetIMlld:pubmed
pubmed-article:11205659pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11205659pubmed:statusMEDLINElld:pubmed
pubmed-article:11205659pubmed:monthFeblld:pubmed
pubmed-article:11205659pubmed:issn0192-0790lld:pubmed
pubmed-article:11205659pubmed:authorpubmed-author:ChurchillD...lld:pubmed
pubmed-article:11205659pubmed:authorpubmed-author:AlexopoulouIIlld:pubmed
pubmed-article:11205659pubmed:authorpubmed-author:MargettsP JPJlld:pubmed
pubmed-article:11205659pubmed:issnTypePrintlld:pubmed
pubmed-article:11205659pubmed:volume32lld:pubmed
pubmed-article:11205659pubmed:ownerNLMlld:pubmed
pubmed-article:11205659pubmed:authorsCompleteYlld:pubmed
pubmed-article:11205659pubmed:pagination176-8lld:pubmed
pubmed-article:11205659pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:11205659pubmed:meshHeadingpubmed-meshheading:11205659...lld:pubmed
pubmed-article:11205659pubmed:meshHeadingpubmed-meshheading:11205659...lld:pubmed
pubmed-article:11205659pubmed:meshHeadingpubmed-meshheading:11205659...lld:pubmed
pubmed-article:11205659pubmed:meshHeadingpubmed-meshheading:11205659...lld:pubmed
pubmed-article:11205659pubmed:meshHeadingpubmed-meshheading:11205659...lld:pubmed
pubmed-article:11205659pubmed:meshHeadingpubmed-meshheading:11205659...lld:pubmed
pubmed-article:11205659pubmed:meshHeadingpubmed-meshheading:11205659...lld:pubmed
pubmed-article:11205659pubmed:meshHeadingpubmed-meshheading:11205659...lld:pubmed
pubmed-article:11205659pubmed:meshHeadingpubmed-meshheading:11205659...lld:pubmed
pubmed-article:11205659pubmed:meshHeadingpubmed-meshheading:11205659...lld:pubmed
pubmed-article:11205659pubmed:year2001lld:pubmed
pubmed-article:11205659pubmed:articleTitleInterstitial nephritis in patients with inflammatory bowel disease treated with mesalamine.lld:pubmed
pubmed-article:11205659pubmed:affiliationDivision of Nephrology, Faculty of Health Sciences, McMaster University Hamilton, Ontario, Canada.lld:pubmed
pubmed-article:11205659pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11205659pubmed:publicationTypeCase Reportslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11205659lld:pubmed